Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, Regina Herbst, Friedrich Stoelzel, Christoph Röllig, Edgar Jost, Richard F. Schlenk, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Goetze, Sebastian Buske, Axel Florschütz, Jörg Schubert, Bernhard Opitz, Martin Mohren, Eva Eßeling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Hemmati, Frank Schueler, Simone Kowoll, Marina Scheller, Jörg Steighardt, Bayram Edemir, Lutz Peter Mueller, Irit Gliko-Kabir, Beatrice Ludwig-Kraus, Sabine Edemir, Ella Sorani, Mascha Binder, Abi Vainstein, Shaul Kadosh, Cora Gromann, Andreas Wienke, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhaeuser, Christian Junghanss, Carsten Mueller-Tidow

Blood (2022) 140 (Supplement 1): 3338–3340.

https://doi.org/10.1182/blood-2022-166748

Published: 2022

Journal Articles

Single Cell Transcriptomic Analysis of the Bone Marrow Microenvironment Uncovers a Role for Antigen Presentation Processes in MDS/AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Jennifer Rivière, Mark van der Garde, Judith S. Hecker, Michèle C. Buck, Florian Bassermann, Mareike Verbeek, Katharina S. Goetze

Blood (2022) 140 (Supplement 1): 2906–2907.

https://doi.org/10.1182/blood-2022-165255

Published: 2022

Journal Articles

Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Klaus H. Metzeler, Eric S. Winer, Uwe Platzbecker, Amit Verma, Daniel J. DeAngelo, Stefano R. Tarantolo, David A. Sallman, James Dugan, Stefanie Gröpper, Katharina S. Goetze, Chia-Cheng Li, Wanying Zhao, Maureen Lane, Reinhard von Roemeling, Samantha Carlisle, Anne Weigert, Matthias Böhme, Anne Sophie Kubasch, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 9048–9049.

https://doi.org/10.1182/blood-2022-167477

Published: 2022

Journal Articles

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Blood (2022) 140 (Supplement 1): 1109–1111.

https://doi.org/10.1182/blood-2022-168718

Published: 2022

Journal Articles

Targeting Extracellular Vesicle Secretion in Combination with Venetoclax Synergistically Induces Apoptosis in FLT3-ITD+ AML

Judith S. Hecker, Jennifer Rivière, Mark van der Garde, Michèle C. Buck, Rupert Öllinger, Florian Bassermann, Bernd Giebel, Robert A.J. Oostendorp, Roland Rad, Katharina S. Goetze

Blood (2022) 140 (Supplement 1): 8711–8712.

https://doi.org/10.1182/blood-2022-169065

Published: 2022

Journal Articles

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, Matthias Stelljes, Verena I Gaidzik, Michael Lauseker, Oliver Kriege, Mareike Verbeek, Julia M. Unglaub, Felicitas Thol, Stefan W. Krause, Mathias Haenel, Charlotte Neuerburg, Vladan Vucinic, Christian Jehn, Julia Severmann, Maxi Wass, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus, William Hermann Krüger, Ulrich Kaiser, Sebastian Scholl, Lea Henning, Guido Kobbe, Rainer Haas, Nael Alakel, Maximilian Alexander Röhnert, Katja Sockel, Maher Hanoun, Uwe Platzbecker, Tobias A. W. Holderried, Anke Morgner, Michael Heuser, Tim Sauer, Katharina S. Goetze, Eva Maria Wagner, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Martin Bornhäuser, Ulrich Germing, Thomas Schroeder, Moritz Moritz Middeke

Blood (2021) 138 (Supplement 1): 33.

https://doi.org/10.1182/blood-2021-153440

Published: 2021

Journal Articles

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Blood (2021) 138 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2021-146468

Published: 2021

Journal Articles

Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers

Laura K. Schmalbrock, Krischan Braitsch, Paul Jung, Irmgard Bumeder, Philipp Kiewe, Jörg Westermann, Lars Bullinger, Ulrich Keller, Florian Bassermann, Jan Krönke, Kathrin Rieger, Katharina S. Goetze

Blood (2021) 138 (Supplement 1): 1257.

https://doi.org/10.1182/blood-2021-150943

Published: 2021

Journal Articles

Characterization of Somatic Mosaicism and Mutational Profiling of Clonal Hematopoiesis Compared to MDS and sAML Depicts Diversities of Clonal Evolution

Blood (2021) 138 (Supplement 1): 3278.

https://doi.org/10.1182/blood-2021-152187

Published: 2021

Journal Articles

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Uwe Platzbecker, MD, Eva Lengfelder, MD, Katharina S Goetze, MD, Christoph Röllig, MD, Michael Kramer, Michaela Sauer, Nadine Albers, Michael Heuser, Hartmut Link, MD PhD, Kerstin Schäfer-Eckart, MD, Sonja Martin, MD, Stefan W. Krause, MD, Mathias Hänel, MD, Tilmann Bochtler, MD, Andreas Jakob, MD, Albrecht Reichle, MD, Harald Biersack, MD, Claudia D. Baldus, MD, Martin Goerner, MD, Nadezda Basara, MD, Joerg Mezger, MD, Ralph Naumann, MD, Dorit Kuerschner, MD, Maike de Wit, Florian Nolte, MD, Mark Ringhoffer, MD, Hans-Joachim Tischler, MD, Jochen Greiner, Stephan Kremers, Sigrid Machherndl-Spandl, MD, Elisabeth Koller, MD, Mohammad Amen Wattad, MD, Gregor Aschauer, MD, Markus Radsak, MD, Thomas Kubin, MD, Helmut Salih, MD, Frank Heits, MD, Dominik Wolf, MD, Christian Thiede, MD, Hubert Serve, MD, Ulrich Duehrsen, MD, Andreas Hochhaus, MD, Tim H. Brümmendorf, MD, Martin Bornhäuser, MD, Hartmut Döhner, MD, Gerhard Ehninger, MD, Richard F. Schlenk, MD

Blood (2016) 128 (22): 2815.

https://doi.org/10.1182/blood.V128.22.2815.2815

Published: 2016

Journal Articles

Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

Blood (2013) 122 (21): 3878.

https://doi.org/10.1182/blood.V122.21.3878.3878

Published: 2013

Journal Articles

Lentivirally Transduced Human Cord Blood CD34 + FLT3-ITD + Cells Induce Murine Acute Leukemia in the NOD/SCID Transplantation Model.

Pawan Kaur Bollinger, PhD, Doris Steinemann, PhD, Rama Krishna Kancha, PhD, Leticia Quantanilla-Fend, MD, Stefan K Bohlander, MD, Christian Peschel, MD, Robert A.J. Oostendorp, PhD, Christopher Baum, MD, Katharina S. Goetze, MD

Blood (2012) 120 (21): 2984.

https://doi.org/10.1182/blood.V120.21.2984.2984

Published: 2012

Journal Articles

GM1 Expression of Non-Hodgkins Lymphoma Determines Susceptibility to Rituximab Treatment.

Christian Meyer zum Bueschenfelde, MD, Yvonne Feuerstacke, Katharina S. Goetze, MD, Kathrin Schlolze, Christian Peschel, MD

Blood (2007) 110 (11): 228.

https://doi.org/10.1182/blood.V110.11.228.228

Published: 2007

Journal Articles

The Combination of Stem Cell Factor and Oncostatin M Maintains Cord Blood-Derived NOD/SCID-Repopulating Cells.

Siv Gilfillan, PhD, Simone Kraner, PhD, Katharina S. Goetze, MD, Matthias Schiemann, PhD, Stefanie Marz, Christian Peschel, MD, PhD, Robert A.J. Oostendorp, PhD

Blood (2005) 106 (11): 4267.

https://doi.org/10.1182/blood.V106.11.4267.4267

Published: 2005

NARROW

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Single Cell Transcriptomic Analysis of the Bone Marrow Microenvironment Uncovers a Role for Antigen Presentation Processes in MDS/AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Targeting Extracellular Vesicle Secretion in Combination with Venetoclax Synergistically Induces Apoptosis in FLT3-ITD+ AML

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers

Characterization of Somatic Mosaicism and Mutational Profiling of Clonal Hematopoiesis Compared to MDS and sAML Depicts Diversities of Clonal Evolution

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

Lentivirally Transduced Human Cord Blood CD34 + FLT3-ITD + Cells Induce Murine Acute Leukemia in the NOD/SCID Transplantation Model.

GM1 Expression of Non-Hodgkins Lymphoma Determines Susceptibility to Rituximab Treatment.

The Combination of Stem Cell Factor and Oncostatin M Maintains Cord Blood-Derived NOD/SCID-Repopulating Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only